2
2
↑2
↓0
—2
Evidence suggests Psilocybin haslittle to no effecton Memory function.
3 studies (4 claims)
Emerging evidence
Typical effective dose 20 (15–25) mgacross 2 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| low-dose oral psilocybin with psychological support | No effect - were unable to collect data as planned on | cognitive function during the acute experience | Human | patients with chronic SUNHA | Ascending doses of 5, 7.5, and 10 mg (one dose per session; three dosing sessions total). | Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.cited 4× |
| microdosing 0.1 g of psilocybin mushrooms three times | Increases - reported olfactory improvement | olfactory function | Human | a woman with COVID-19-related anosmia | 100 µg of LSD (single dose). | Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD.cited 5× |
| Psilocybin | Increases - improvements | executive function | Human | patients with treatment-resistant depression (TRD) | Macrodoses ranging from 45 μg/kg to 30 mg/70 kg. | Impact of psilocybin on cognitive function: A systematic review.cited 5× |
| Psilocybin | No effect - remained mostly unchanged | global cognitive function | Human | healthy individuals | Macrodoses ranging from 45 μg/kg to 30 mg/70 kg. | Impact of psilocybin on cognitive function: A systematic review.cited 5× |